Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab

(2012) Chamaida Plasencia et al.   ANNALS OF THE RHEUMATIC DISEASES

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation

(2012) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

(2012) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

(2012) J. Leman et al.   BRITISH JOURNAL OF DERMATOLOGY

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

(2012) Hidetoshi Takahashi et al.   JOURNAL OF DERMATOLOGY

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

(2011) Zoe Ash et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

(2011) D. Pascual-Salcedo et al.   RHEUMATOLOGY

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study

(2011) Denis Mulleman et al.   ARTHRITIS RESEARCH & THERAPY

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

(2011) Emilie Ducourau et al.   ARTHRITIS RESEARCH & THERAPY

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

(2010) A. W. R. van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis

(2010) Lidian L. A. Lecluse et al.   ARCHIVES OF DERMATOLOGY

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

(2010) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

The immunogenicity of humanized and fully human antibodies

(2010) Fiona A. Harding et al.   mAbs

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the Tumor Necrosis Factor Antagonists

(2010) F. Bachmann et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study

(2009) A.E. Pink et al.   BRITISH JOURNAL OF DERMATOLOGY

Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases

(2009) Nádia Emi Aikawa et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Adalimumab for the treatment of psoriatic arthritis

(2009) Denis A Poddubnyy et al.   Expert Review of Clinical Immunology

Dermatological complications and safety of anti-TNF treatments

(2009) J. F. Kerbleski et al.   GUT

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

(2008) Arie E. van der Bijl et al.   CLINICAL RHEUMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY